Form 4: NewAmsterdam Pharma Co. Chief Accounting Officer Acquires 80,000 Stock Options

Louise Frederika Kooij, Chief Accounting Officer of NewAmsterdam Pharma Co. N.V., acquired 80,000 stock options on January 2, 2025.

Summary

• Louise Frederika Kooij, the Chief Accounting Officer of NewAmsterdam Pharma Co. N.V., has reported the acquisition of 80,000 stock options.
• The options were granted on January 2, 2025, with an exercise price of $25.96 per share.
• The options vest over a four-year period, with 25% vesting on January 2, 2026, and the remaining vesting monthly over the following three years.
• The vesting is contingent upon Ms. Kooij's continued employment with the company.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management's interests with shareholders. There are no indications of negative news or concerns.

Positives

• The grant of stock options to a key executive like the Chief Accounting Officer aligns her interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Risks

• The value of the options is dependent on the future performance of the company's stock price.
• If Ms. Kooij leaves the company before the options fully vest, she may forfeit some or all of the options.

Industry Context

This is a standard practice for incentivizing key executives in publicly traded companies, particularly in the pharmaceutical industry where long-term growth and value creation are crucial.

Comparison to Industry Standards

• Stock option grants are a common form of compensation for executives in the pharmaceutical industry, similar to companies like Amgen, Gilead Sciences, and Regeneron.
• The vesting schedule of four years with a cliff vest after one year followed by monthly vesting is also a typical structure seen in many companies.
• The exercise price of $25.96 would be compared to the current market price of the stock to determine the value of the options.

Stakeholder Impact

• Shareholders may view this positively as it incentivizes the Chief Accounting Officer to contribute to the company's long-term success.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, insider trading, executive compensation, NewAmsterdam Pharma, NAMS, Louise Kooij, Chief Accounting Officer